Metabolic and endocrine alterations in end-stage renal failure.
Many alterations in metabolic and endocrine function occur in end-stage renal disease. Glucose intolerance is almost always present with uremia; it improves shortly after institution of regular hemodialysis. Hyperlipidemia (type IV) is prevalent, and atherosclerotic cardiovascular disease causes death in about 50% of patients receiving long-term hemodialysis. Although plasma levels of growth hormone usually are elevated, children with chronic renal failure show growth retardation. The occurrence of thyroid disorders is difficult to determine, since many clinical features of uremia are similar to those of hyperthyroidism and hypothyroidism. The incidence of duodenal ulcer is high, possibly due to high gastrin levels. Sex hormone disturbances are common. Anemia is a constant feature of chronic renal failure; patients usually tolerate it well.
D000740:Anemia / Q000209:etiology; D001786:Blood Glucose / Q000378:metabolism; D005755:Gastrins / Q000097:blood; D012739:Gonadal Steroid Hormones / Q000097:blood; D013006:Growth Hormone / Q000097:blood; D006801:Humans; D006949:Hyperlipidemias / Q000209:etiology; D007328:Insulin / Q000378:metabolism; D007676:Kidney Failure, Chronic / Q000150:complications; D006435:Renal Dialysis; D013959:Thyroid Diseases / Q000150:complications / Q000175:diagnosis; D014280:Triglycerides / Q000097:blood; D014511:Uremia / Q000150:complications / Q000378:metabolism*
D001786:Blood Glucose; D005755:Gastrins; D012739:Gonadal Steroid Hormones; D007328:Insulin; D014280:Triglycerides; D013006:Growth Hormone